Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abera Bioscience ABFRA:8WK 40 Cash Ratio is 3.89 as of Jun. 2026, which is 37% above its 10-year median of 2.83. GuruFocus rates FRA:8WK with a GF Score™ of 40/100. The stock has 1 warning sign investors should review. Among 1,382 Biotechnology companies, Abera Bioscience AB ranks better than 57.31% on this metric.
Abera Bioscience AB has a Cash Ratio of 3.89. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Abera Bioscience AB's Cash Ratio or its related term are showing as below:
FRA:8WK'
s Cash Ratio Range Over the Past 10 Years
Min: 0.25 Med: 2.83 Max: 18.26
Current: 3.89
During the past 8 years, Abera Bioscience AB's highest Cash Ratio was 18.26. The lowest was 0.25. And the median was 2.83.
FRA:8WK's Cash Ratio is ranked better than 57.31% of 1382
companies
in the Biotechnology industry
Industry Median: 2.93
vs FRA:8WK: 3.89
Abera Bioscience AB (FRA:8WK) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Abera Bioscience AB Cash Ratio Related Terms
Abera Bioscience AB Cash Ratio Historical Data
* Premium members only.
The historical data trend for Abera Bioscience AB's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8WK vs VRTX, REGN, MRNA: Cash Ratio Comparison
For the Biotechnology subindustry, Abera Bioscience AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abera Bioscience AB Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abera Bioscience AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Abera Bioscience AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abera Bioscience AB (FRA:8WK) has a Cash Ratio of 3.89 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Abera Bioscience AB and its competitors. This is 37% above median its historical median of 2.83. Over the past decade, Abera Bioscience AB's Cash Ratio has ranged from 0.25 to 18.26. According to the industry distribution chart, Abera Bioscience AB ranks #590 out of 1382 companies in the Biotechnology industry, placing it in the top 42.7%.
Is Abera Bioscience AB's Cash Ratio too high?
Abera Bioscience AB's current Cash Ratio of 3.89 is 37% above median its 10-year median of 2.83. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 18.26. The Biotechnology industry median Cash Ratio is 2.93. Abera Bioscience AB's value of 3.89 is 32.8% above this industry median. Based on the distribution chart, Abera Bioscience AB ranks #590 out of 1382 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Abera Bioscience AB has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Abera Bioscience AB's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abera Bioscience AB ranks #590 out of 1382 companies for Cash Ratio. This puts Abera Bioscience AB in the upper half of its industry. The industry median Cash Ratio is 2.93. Abera Bioscience AB's value of 3.89 is 32.8% above this benchmark. Historically, Abera Bioscience AB's own Cash Ratio has ranged from 0.25 to 18.26 over the past decade. While the company's 10-year median is 2.83 vs. the industry median of 2.93, Abera Bioscience AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,382 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abera Bioscience AB's current Cash Ratio of 3.89 is 32.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Abera Bioscience AB and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abera Bioscience AB's current Cash Ratio is 3.89, which is 37% above median its own 10-year median of 2.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abera Bioscience AB stock overvalued right now?
Abera Bioscience AB (FRA:8WK) has a current Cash Ratio of 3.89. The current Cash Ratio is 3.89, which is 37% above median its 10-year median of 2.83 and 32.8% above the Biotechnology industry median of 2.93. Abera Bioscience AB's overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Abera Bioscience AB (FRA:8WK), the current Cash Ratio is 3.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Abera Bioscience AB is a platform and vaccine development company based on research in the medical, molecular, and microbiological fields. The company's mission is to develop vaccine candidates based on its novel vaccine delivery platform to late pre-clinical or early clinical phase.
40GF Score
Get the complete analysis for FRA:8WK
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8WK has been successfully added to your 
